Supreme Court declines to hear pharma challenges to Medicare drug price negotiations

The U.S. Supreme Court has refused to review several lawsuits filed by drug makers contesting the Medicare drug price negotiation provisions of the Inflation Reduction Act. The cases, brought by companies such as AstraZeneca and Johnson & Johnson, sought to block the government’s authority to set prices for certain high‑cost medicines.

By declining to take the cases, the Court leaves the lower‑court rulings in place, meaning the negotiations will proceed as scheduled under the law. The decision does not resolve the underlying legal arguments, and the pharmaceutical industry may continue to pursue other legal avenues.

The outcome signals that the highest court is not ready to intervene in this contentious policy area, at least for now, leaving the industry to adapt to the new pricing framework.